Institute for Molecular Medicine Finland

To investigate whether periodontitis is associated with prevalent and incident metabolic syndrome (MetS).

The baseline study included 4183 individuals from a population‐based survey (DILGOM) in 2007 and follow‐up of 1047 participants with clinical re‐examination in 2014. The risk of periodontitis was assessed with saliva biomarkers using a validated, three‐group cumulative risk score for periodontitis (CRS I, II and III).

In fully adjusted models, CRS III was associated with prevalent MetS (OR: 1.35, 95% CI [1.11–1.65]), high waist circumference (1.55 95% CI [1.26–1.91]), high blood pressure (1.29 95% CI [1.05–1.59]) and the number of MetS components (β: 0.18, 95% CI [0.06–0.30]). Among participants without MetS at baseline ( n  = 618), 128 (20.7%) developed MetS during follow‐up. In the fully adjusted model, CRS III trended positively with incident MetS (RR: 1.55, 95% CI [ 0.96–2.51]) in the whole population and had a significant positive association in women (2.06, 95% CI [1.08–3.94]), and in non‐smokers (1.78, 95% CI [1.01–3.14]). The risk between CRS and incident MetS was mediated via systemic inflammation.

Periodontitis is associated with an increased risk of having metabolic syndrome and, in particular, clearly with the number of MetS components: abdominal obesity, hyperglycaemia and hypertension. Systemic inflammation may elucidate the observed higher risk of incident MetS.

Nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (N-ERD) is a common chronic airway inflammatory disease characterised by asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) and hypersensitivity to NSAIDs, including acetylsalicylic acid (ASA, aspirin), posing a significant burden on respiratory health [1]. N-ERD currently lacks reliable clinical laboratory tests, yet early diagnosis and management are essential to prevent disease progression [2]. The pathogenesis of N-ERD has been linked to dysregulation of arachidonic acid (AA) metabolism, which affects levels of pro-inflammatory lipid mediators such as leukotrienes and prostaglandins [1, 3]. ASA alters AA metabolism by inhibiting cyclooxygenase (COX) enzymes and redirecting lipid synthesis towards pro-inflammatory leukotrienes [1]. Despite extensive research into eicosanoids in N-ERD, the full spectrum of lipid mediators involved remains incompletely understood. In this study, we investigated the effect of a low dose of ASA (25 mg) on plasma and urine lipid mediator concentrations in N-ERD patients compared with healthy controls, aiming to identify novel biomarkers and deepen understanding of disease mechanisms. This study included eight consecutively recruited N-ERD patients and seven age-matched healthy controls (25–62 years). All subjects were Finnish females, selected to minimise demographic variability. N-ERD was diagnosed based on typical symptoms after NSAID intake and confirmed with ASA challenge, lung function testing and clinical examination [1]. All patients had asthma and CRSwNP. Ethics approval and informed consent were obtained as part of the AirGOs-Medical clinical trial (NCT03825757) [4]. Blood plasma and urine samples were collected after overnight fasting at baseline and 2 h after ingestion of 25 mg ASA (Primaspan, 50 mg tablet, Orion, Espoo, Finland). Although this initial dose did not provoke symptoms in all patients, it was part of a broader challenge that ultimately confirmed N-ERD in each case (Figure 1A). Our aim was to detect metabolic changes while minimising the risk of severe respiratory reactions. Lipid mediators were quantified using liquid chromatography–tandem mass spectrometry, targeting 158 eicosanoids and related compounds, with 30 analytes quantified. Urine concentrations were normalised to creatinine levels. Linear mixed-effects models were used to evaluate the effects of group (N-ERD vs. control), ASA intake (before vs. after) and their interaction (different ASA effects between groups) on individual lipid concentrations. Lipids with a significant p value (p < 0.05) in the group comparison were considered main findings and are presented in this letter. Reduced plasma concentrations of the endocannabinoid-related lipids arachidonoylethanolamide (AEA) and oleoylethanolamide (OEA) were associated with N-ERD both at baseline and after ASA ingestion, compared with the control group (p < 0.01 for both) (Figure 1B). AEA and OEA are N-acylethanolamines (NAEs), lipid mediators derived from membrane phospholipids, from which AA can also be released by phospholipase A2 (PLA2) (Figure 1C). AEA and OEA exert anti-inflammatory effects via distinct pathways: AEA through cannabinoid type 2 receptors (CB2R), reducing pro-inflammatory cytokines and OEA via peroxisome proliferator-activated receptor alpha (PPAR-α), which suppresses cytokine production, eosinophil recruitment and oxidative stress. Both NAEs are further metabolised by COX-2, lipoxygenase (LOX) and cytochrome P450 (CYP450) enzymes into immunomodulatory metabolites [5]. Lower plasma AEA and OEA levels in N-ERD suggest dysregulated NAE metabolism and impaired CB2R- and PPAR-α-mediated anti-inflammatory signalling, with unchanged levels after ASA indicating impaired synthesis or downstream conversion. The endocannabinoid system is a conserved signalling network that modulates eicosanoid-driven inflammation. CB2R activation reduces type 2 inflammation and AA levels, and its expression is upregulated in nasal polyp tissue of N-ERD patients [6], suggesting a compensatory mechanism. Thus, reduced AEA and OEA levels may reflect negative feedback, explaining symptom severity, poor response to traditional management [7] and the potential role of biologics in N-ERD [2]. Plasma leukotriene E4 (LTE4) levels were significantly higher in the N-ERD group at both time points (p < 0.01). After ASA ingestion, LTE4 increased significantly in N-ERD, while remaining below quantification in controls (group × ASA interaction p < 0.05) (Figure 1B). As a pro-inflammatory mediator produced via the 5-LOX pathway (Figure 1C), elevated LTE4 supports its role in N-ERD pathophysiology and utility as a biomarker, as previously shown [3]. Plasma 12-hydroxyheptadecatrienoic acid (12-HHT) was significantly elevated in the N-ERD group at both time points (p < 0.05) (Figure 1B). 12-HHT, an AA-derived mediator, suppresses allergic airway inflammation through leukotriene B4 receptor 2 (BLT2) activation (Figure 1C) [8]. Elevated levels may reflect ongoing chronic airway inflammation in N-ERD and hold diagnostic potential. Plasma eicosapentaenoic acid (EPA) was consistently significantly lower in the N-ERD group (p < 0.05) (Figure 1B). EPA is an omega-3 fatty acid produced from alpha-linolenic acid by fatty acid desaturase 2 (FADS2) (Figure 1C), which is a precursor for pro-resolving mediators, competes with AA for COX enzymes and suppresses inflammatory cytokines. Reduced levels may reflect dietary insufficiency or altered omega-3 metabolism, potentially contributing to allergic airway inflammation in N-ERD, as EPA has a protective role against the development of asthma and allergic diseases [9]. None of the measured lipid mediators in urine showed a statistically significant p value in the group comparisons. Detailed results also for other analysed lipids are available in the following repository: https://osf.io/eazn6/?view_only=6b8eff58edfc4c43a76d811680f93732. To our knowledge, this is the first report demonstrating an association between reduced plasma concentrations of endocannabinoid-related lipids AEA and OEA with N-ERD. Impaired AEA or OEA signalling may contribute to heightened pain perception in N-ERD patients [5], suggesting potential diagnostic and therapeutic implications. We also discovered other lipids that are potentially characteristic of N-ERD metabolism. Further studies with a larger cohort are needed to confirm these findings. S.T.-S. and A.L.: recruitment of subjects, examination of subjects, sampling. M.Ni. and M.Ne.: laboratory experiments, data preparation. V.E.S.: data analysis, writing of manuscript, preparation of figures and tables. All authors have made substantial contributions to conception and design, or interpretation of data, and have been involved in revising the manuscript critically and have given final approval of the version to be published. The authors thank research nurse and bioanalyst Minna Niemi and research nurses Eija Mäkinen-Pulli, Lisbet Partanen and Meeri Alanappa for excellent technical assistance in the clinical trial and sample handling. In addition, the authors thank bioanalysts Henrika Werling and Alli Tallqvist for excellent assistance in the study. We express our deepest gratitude to patients and volunteers for participating in this study. Declaration of Generative AI and AI-Assisted Technologies in the Writing Process: During the preparation of this work, the authors used ChatGPT-4 in order to improve grammar, spelling and the overall readability of the text. After using this tool/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication. Open access publishing facilitated by Helsingin yliopisto, as part of the Wiley - FinELib agreement. Approval for the study was obtained from the National Drug Agency (Eudra CT 2017-0015070-42, KL/41/2018), Ethics Committee of Hospital District of Helsinki and Uusimaa (HUS/1801/2017). Written informed consent was obtained from all subjects. S.T.-S. reports consultancies for ALK-Abelló, AstraZeneca, Clario, ERT, GlaxoSmithKline, Novartis, Sanofi Pharma, Orion Pharma, Roche Products and grants from GlaxoSmithKline and Sanofi. All are outside the submitted work. A.L. reports a consultancy for AstraZeneca and a lecturing fee from the Finnish Lung Health Association. All are outside the submitted work. All other authors declare no conflicts of interest. Additional information about study methods and results is available in the following repository: https://osf.io/eazn6/?view_only=6b8eff58edfc4c43a76d811680f93732. The data that support the findings of this study are available upon request from the corresponding author.

Despite the clinical success of tropomyosin receptor kinases (TRKs) inhibitors in NTRK fusion-positive cancers, prolonged administration has resulted in acquired resistance, particularly xDFG mutations, for which no approved therapies are available. Herein, we first presented a series of bifunctional agents as potent TRK inhibitors and degraders featuring a novel 5-amino-4-carbamoylpyrazole scaffold. The representative compounds 19 and 20 demonstrated potent antiproliferative activities against Ba/F3-LMNA-NTRK1^G667C cells with IC₅₀ values of 0.29 and 2.48 nM, respectively, and induced pronounced TRKA G667C degradation (DC₅₀ = 5.86 and 24.69 nM; D_max > 90%), while sparing the wild-type protein. Further in vivo assay displayed that 20 effectively inhibited tumor growth with no apparent toxicity in the Ba/F3-LMNA-NTRK1^G667C xenograft model. Overall, these findings indicated that, unlike conventional inhibitors, such bifunctional agents represent the first class of monovalent small molecules capable of effectively degrading TRK xDFG mutants, providing valuable insights into overcoming TRK xDFG-mediated clinical resistance.